✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Both are dual agonists. Survodutide = GLP-1 + glucagon. Tirzepatide = GLP-1 + GIP. The differentiator is glucagon vs GIP.
- Tirzepatide has regulatory precedent. Mounjaro and Zepbound are FDA-approved. Survodutide is in Phase 2/3 with no approved product.
- Hepatic / MASH activity differs sharply. Survodutide’s glucagon arm produces substantial fibrosis-resolution effects in MASH. Tirzepatide’s effect on liver is more modest.
- Weight-loss readouts: Survodutide -18.7% at 46 wk (4.8 mg). Tirzepatide -22.5% at 72 wk (15 mg). Different timeframes, slightly different effect-size positioning.
- This guide compares the two dual-agonist architectures and where each fits in research-protocol design.
Survodutide vs Tirzepatide: GLP-1 / Glucagon Dual vs GLP-1 / GIP Dual Compared
Both molecules are dual-receptor incretin agonists — both add a second receptor arm on top of GLP-1, but they pick different second arms. Tirzepatide adds GIP (enteroinsular axis); survodutide adds glucagon (hepatic energy expenditure). The architectural difference produces different downstream pharmacology, particularly in hepatic-lipid endpoints. This guide compares them on mechanism, trial data, and research applicability.
Quick verdict
- Regulatory precedent / clinical-grade comparator: Tirzepatide (Mounjaro / Zepbound FDA-approved).
- MASH / fatty-liver-specific research: Survodutide. Glucagon arm produces substantially deeper fibrosis-resolution effects.
- Maximum effect-size research: Tirzepatide (-22.5% at 72 wk) marginally deeper than survodutide (-18.7% at 46 wk).
- Mechanism-isolation research (GIP vs glucagon): Both in the same protocol — the contrast isolates which second arm contributes which effect.
Mechanism: GIP vs glucagon as the second arm
GLP-1 is the shared first arm of both molecules. The pharmacology of GLP-1 monoagonism (appetite suppression + slowed gastric emptying + central satiety) is well-characterised through semaglutide and earlier GLP-1 agonists.
The second-arm architectures diverge:
- Tirzepatide adds GIP. Glucose-dependent insulinotropic polypeptide activates the enteroinsular axis, deepening satiety and (per published mechanism research) attenuating the GI-side-effect profile somewhat. Tirzepatide produces the deeper weight-loss effect in side-by-side timeframe-matched comparison with semaglutide.
- Survodutide adds glucagon. Glucagon-receptor activation increases hepatic glucose mobilisation and direct hepatic energy expenditure — raising basal metabolic rate via a different pathway than appetite suppression. The hepatic-lipid effect is particularly striking: Phase 2 MASH-specific data showed substantially higher fibrosis-resolution rates than GLP-1 monoagonism alone.
For research-protocol design, the two architectures answer different questions. Tirzepatide is the cleaner GLP-1 + GIP mechanism study; survodutide is the cleaner GLP-1 + glucagon mechanism study. Retatrutide (the triple agonist) combines both.
Trial data side by side
| Trial | Molecule | Mean weight loss | Duration | Top dose |
|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide | -22.5% | 72 wk | 15 mg weekly |
| Phase 2 (Boehringer) | Survodutide | -18.7% | 46 wk | 4.8 mg weekly |
Tirzepatide’s depth advantage at matched-duration windows is modest. The substantial differentiator is MASH / hepatic-fibrosis endpoint — where survodutide’s glucagon arm produces effects substantially larger than tirzepatide’s GIP arm.
Comparison table
| Property | Survodutide | Tirzepatide |
|---|---|---|
| Receptor arms | GLP-1 + glucagon | GLP-1 + GIP |
| Developer | Boehringer Ingelheim | Eli Lilly |
| CAS | 2406796-94-9 | 2023788-19-2 |
| Comparator drug status | Phase 2/3 (no approved product) | Mounjaro (FDA 2022) / Zepbound (FDA 2023) |
| Weight-loss readout | -18.7% (46 wk, 4.8 mg) | -22.5% (72 wk, 15 mg) |
| MASH / fibrosis-resolution data | Strong (glucagon arm) | Modest |
| Half-life | ~6 days | ~5 days |
| Dosing | Weekly SC, titrate to 4.8 mg | Weekly SC, titrate to 15 mg |
Which to pick (research-protocol logic)
- Regulatory-precedent dual-agonist research: Tirzepatide. Both Mounjaro (diabetes) and Zepbound (obesity) are FDA-approved.
- MASH / fatty-liver-specific research: Survodutide. The glucagon-arm hepatic-fibrosis effect is the cleanest published in this class.
- GLP-1 / glucagon mechanism research (no GIP confound): Survodutide or mazdutide.
- GLP-1 / GIP mechanism research (no glucagon confound): Tirzepatide.
- Mechanism-isolation research: Direct head-to-head of survodutide and tirzepatide at matched GLP-1 occupancy — the contrast isolates GIP vs glucagon contribution.
- Maximum effect-size: Move to retatrutide (triple agonist combines both second arms).
Safety and regulatory status
Tirzepatide’s comparator drugs Mounjaro and Zepbound are FDA-approved; the research-grade lyophilized peptide on the catalogue is not the finished pharmaceutical product. Survodutide has no FDA-approved comparator drug. Both compounds are sold for in-vitro laboratory research and analytical reference use only. Class-level safety considerations include GI side effects, hypoglycaemia risk, gallstone formation with rapid weight loss, and the rare pancreatitis signal seen across the incretin class. None of this is medical advice.
FAQ
Why does the glucagon arm produce hepatic effects that GIP doesn’t?
Because glucagon directly targets hepatic metabolism. The glucagon receptor is heavily expressed on hepatocytes, and glucagon activation increases hepatic glucose output, fatty-acid oxidation, and direct hepatic energy expenditure. GIP’s primary action is on islet cells and adipose tissue rather than hepatocytes. For MASH / fatty-liver research where the hepatic-lipid endpoint is primary, the glucagon-arm-containing molecule is mechanistically superior.
Why is tirzepatide deeper in pure weight-loss readout if both add a second arm?
The deeper effect size at matched timeframes likely reflects (a) longer follow-up duration in SURMOUNT-1 (72 wk vs survodutide’s 46 wk), (b) the GIP arm’s specific contribution to appetite suppression beyond the GLP-1 baseline, and (c) higher absolute dose ladder (15 mg vs 4.8 mg, reflecting different receptor-affinity profiles). The deeper readout is not necessarily a sign that GIP is “better than” glucagon at weight loss — the architectures answer different research questions.
Will survodutide get FDA approval?
Boehringer Ingelheim is advancing the molecule through Phase 2/3 trials. As of catalogue date no approval timeline is public. The molecule’s strongest case may be for MASH / NASH indications specifically (where the glucagon-arm effect on hepatic fibrosis is the differentiator) rather than pure obesity indications (where tirzepatide already has FDA approval).
Can either replace retatrutide in research-protocol design?
Both can substitute for retatrutide in specific mechanism-isolated research, but not for the maximum-effect-size research where retatrutide’s triple-arm architecture is the design point. Survodutide isolates the GLP-1 + glucagon mechanism; tirzepatide isolates the GLP-1 + GIP mechanism; retatrutide combines them.
What’s the storage protocol?
Lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Bottom line
Survodutide and tirzepatide are both dual incretin agonists with the GLP-1 arm shared but the second arm differing — glucagon for survodutide, GIP for tirzepatide. Tirzepatide is the FDA-approved-comparator molecule with deeper raw weight-loss readouts in pure obesity research. Survodutide is the MASH / hepatic-fibrosis-specific molecule with the glucagon-arm producing substantially deeper liver effects. Both have valid research-protocol roles depending on the endpoint of interest. See Best peptides for fat loss for full cluster context.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.